利用肺动脉高压临床站点和患者视角（PERSIST）影响马昔腾坦和司来帕格患者持续治疗率的实践：一项美国定性分析
Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis.
作者信息
Shlobin Oksana A, Bruce Gary, Gomez-Rendon Gabriela, Kingman Martha, Rahman Mohammad, Rogers Frances, Studer Sean, Tobore Tobore, McEvoy Colleen
机构信息
Advanced Lung Disease and Transplant Program Inova Fairfax Hospital Falls Church Virginia USA.
Patient author Dallas Texas USA.
出版信息
Pulm Circ. 2024 Oct 11;14(4):e12441. doi: 10.1002/pul2.12441. eCollection 2024 Oct.
This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.
这项真实世界研究从23名医疗保健专业人员（HCPs）和134名肺动脉高压患者的角度，探讨了2019年至2022年期间影响马昔腾坦和司来帕格治疗持续性的因素。患者/医疗保健专业人员之间持续的沟通和教育是治疗持续性的关键驱动因素，副作用的早期讨论和管理也是如此。
Zotero 插件